Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Amryt to enrol youngest patients to test potential EB treatment with market value more than €1 billion
February 28, 2019 Off

Amryt to enrol youngest patients to test potential EB treatment with market value more than €1 billion

By Dino Mustafić

Amryt Pharma can now enrol young Epidermolysis Bullosa (EB) patients between the ages of 21 days to 4 years old to test AP101 as a potential treatment.

February 28, 2019 Off

Galderma’s skin acne targeting cream meets all goals in Phase three test

By Dino Mustafić

Galderma’s Phase 3 “Perfect” 2 clinical trials of Trifarotene, an investigational drug, against acne, with 2,400 patients met all primary and secondary efficacy endpoints, the company said Thursday.

Heron’s Civanti supplemental NDA accepted by FDA
February 27, 2019 Off

Heron’s Civanti supplemental NDA accepted by FDA

By Dino Mustafić

Heron Therapeutics said Wednesday that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for Cinvanti (aprepitant) injectable emulsion, for intravenous (IV) use.

Bayer gets closer to have darolutamide as a potential treatment option for men with nmCRPC
February 27, 2019 Off

Bayer gets closer to have darolutamide as a potential treatment option for men with nmCRPC

By Dino Mustafić

darolutamide

Acrux’s ACX-362E therapeutically relevant for patients with CDI
February 27, 2019 Off

Acrux’s ACX-362E therapeutically relevant for patients with CDI

By Dino Mustafić

Acurx Pharmaceuticals’ recently completed test showed that at well-tolerated doses ACX-362E reaches concentrations in the colon that are projected to be therapeutically relevant for patients with Clostridioides difficile infection (CDI).

February 26, 2019 Off

Debiopharm set to test its antibiotic to treat severe bone and joint infections in phase 2 clinical trial

By Dino Mustafić

Debiopharm International, a Swiss-based global biopharmaceutical company, has started testing its antibiotic afabicin (Debio 1450) for the treatment of staphylococcal bone and joint infections in a clinical phase II study.

Veracyte increases revenue to $92M, in turn sees 26% improvement in net loss 2018
February 26, 2019 Off

Veracyte increases revenue to $92M, in turn sees 26% improvement in net loss 2018

By Dino Mustafić

Veracyte delivered growth in 2018 and are off to a strong start in 2019, as it posted $92.0 million revenue for full year, an increase of 28%, with net loss of $23.0 million, an improvement 26%.

Cellectis has new ways to Improve the safety of CAR T-cell therapy and prevent CRS
February 26, 2019 Off

Cellectis has new ways to Improve the safety of CAR T-cell therapy and prevent CRS

By Dino Mustafić

Cellectis developed engineered GMCSF Knock-Out CAR T-cells through TALEN-mediated gene inactivation, which found to prevent secretion of pro-inflammatory cytokines by monocytes, without compromising CAR T-cell anti-tumor activity, thebiopharmaceutical company said Tuesday in a press release.

February 26, 2019 Off

Halo Labs, Cannus in biomass procurement and extract supply deal

By Dino Mustafić

Halo Labs and Cannus Partners Inc., have made a deal in whcih Cannus will provide Halo with 1,500 pounds of cannabis product (biomass) per week and in return Halo shall manufacture and supply Cannus 50,000 grams of high-grade distillate per week.

Oxford BioMedica appoints WHP to deliver key expansion project
February 26, 2019 Off

Oxford BioMedica appoints WHP to deliver key expansion project

By Dino Mustafić

Multi-disciplinary engineering company WHP has secured the design, construction and project management contract for the development of a new viral vector manufacturing centre for Oxford BioMedica.

Posts pagination

Previous 1 … 3,362 3,363 3,364 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine